| Clinical data | |
|---|---|
| Other names | FMPA; 9α-Fluoromedroxy |
| Routes of administration | By mouth |
| Drug class | Angiogenesis inhibitor;Progestogen;Progestogen ester;Progestin;Glucocorticoid |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C24H33FO4 |
| Molar mass | 404.522 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Fluoromedroxyprogesterone acetate (FMPA,9α-fluoromedroxyprogesterone acetate, or9α-FMPA) is asyntheticsteroid medication which was under development by Meiji Dairies Corporation in the 1990s and 2000s for the potential treatment ofcancers but was never marketed.[1][2][3][4][5][6][7] It is described as anantiangiogenic agent, with about two orders of magnitude greaterpotency for inhibition ofangiogenesis than itsparent compoundmedroxyprogesterone acetate.[2][4][5] FMPA showed about the sameaffinities for theprogesterone andglucocorticoid receptors as MPA.[4] It reached thepreclinical phase of research prior to the discontinuation of its development.[1]
Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byadding missing information. |